Skip to content

T-MACS Decision Aid: a Randomized, Controlled Point of Care Trial

Troponin-only Manchester Acute Coronary Syndromes Decision Aid to Reduce Unnecessary Hospitalisation for Patients With Chest Pain: a Randomized, Controlled Point of Care Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04313465
Enrollment
0
Registered
2020-03-18
Start date
2021-01-31
Completion date
2021-08-31
Last updated
2021-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chest Pain, Heart Attack

Keywords

T-MACS

Brief summary

The aim of the study is to establish whether the safety of the T-MACS decision aid to immediately 'rule out' acute coronary syndromes with one blood sample for the cardiac damage marker troponin, is non-inferior to an approach requiring serial troponin sampling over three hours.

Detailed description

We will conduct a randomized, controlled point of care trial embedded in routine practice. We will ask clinicians to obtain written informed consent during the course of their clinical duties. Patients who have suspected cardiac chest pain, who are identified as being at very low risk by the T-MACS algorithm, will be invited to participate. Patients will then be randomly allocated to be advised that they can be discharged immediately (so long as the doctor and patient have no other concerns; this is the originally intended use of T-MACS; intervention arm) or to receive a second blood test after 3 hours (current practice; control arm). Participants will then be followed up by electronic record review after 30 days and 12 months. Other than the difference in the requirement for a second blood test, participants will not notice any change to their care. The accelerated pathway (involving a single blood test) has been shown to be safe in observational research involving over 5,000 patients. All of the data that are collected are the same of those that are collected in routine care, and they will be anonymised for analysis.

Interventions

OTHERImmediate discharge

Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid

Sponsors

Manchester University NHS Foundation Trust
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* \>18 years of age * Presents to the Emergency Department with pain, discomfort or pressure in the chest, epigastrium, neck, jaw, or upper limb without an apparent non-cardiac source which the treating physician believes warrants investigation for possible acute coronary syndrome * The patient is identified as being at 'very low risk' by the T-MACS decision aid following a single hs-cTn test at the time of arrival in the Emergency Department

Exclusion criteria

* No capacity to provide informed consent * Inability to communicate in English language if translation services are unavailable * Patient is a prisoner * No NHS number (precluding electronic follow up)

Design outcomes

Primary

MeasureTime frameDescription
The incidence of major adverse cardiac event30 daysThis is defined as cardiovascular death or acute myocardial infarction (including prevalent acute myocardial infarction at the time of initial attendance)

Secondary

MeasureTime frameDescription
The incidence of coronary revascularization30 daysIf the participant has had a cardiac bypass or has had stents inserted to improve blood flow
Length of initial hospital stay30 daysHow long the participant was in hospital for after Emergency Department admission
The incidence of cardiovascular death or acute myocardial infarction1 yearIf the patient has had another cardiac episode, or if the participant has died due to a heart attack

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026